Taysha Gene Therapies 

Yahoo Finance • 20 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monog... Full story

Yahoo Finance • last month

Earnings call transcript: Taysha Gene's Q2 2025 revenue beats forecast

Taysha Gene Therapies Inc. reported its financial results for the second quarter of 2025, revealing a notable revenue beat compared to forecasts. The company posted a revenue of $1.98 million, surpassing the expected $1.82 million, marking... Full story

Yahoo Finance • last month

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated... Full story

Yahoo Finance • 2 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • 2 months ago

Cumberland Pharmaceuticals Leads The Charge With 2 Other Prominent Penny Stocks

As the U.S. stock market experiences fluctuations with major indices like the Dow Jones and S&P 500 retreating from early-session gains, investors are keenly observing economic indicators and trade developments. Amid these broader market d... Full story

Yahoo Finance • 2 months ago

BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating

Investing.com - BofA Securities initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and a price target of $8.00 on Friday. The stock, currently trading at $2.55, has shown strong momentum with a 45% gain over the pa... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $17.23 as of... Full story

Yahoo Finance • 3 months ago

Taysha Gene Therapies' SWOT analysis: promising Rett syndrome therapy boosts stock outlook

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), with a market capitalization of $545 million, has emerged as a prominent player in the gene therapy space, focusing on developing treatments for central nervous system (CNS) disorders. The stock h... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogen... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogen... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment... Full story

Yahoo Finance • 12 months ago

Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada Protocol amendment broadens TSHA-102 trea... Full story

Yahoo Finance • 2 years ago

Insider Buying: Taysha Gene Therapies Board Observer Bought US$163k Of Shares

Investors who take an interest in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) should definitely note that the Board Observer, Paul Manning, recently paid US$1.63 per share to buy US$163k worth of the stock. However, it only increased shareho... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of 20-week assessment with sustained improvement across key efficacy measures and new improvement in R-MBA, PGI-I... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

DALLAS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

In vitro data demonstrated the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models Data recapitulate in vivo findings in neonatal mice demonstrating TS... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the... Full story

Yahoo Finance • 2 years ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review Dosing of third a... Full story